Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07209449 · ClinicalTrials.gov registry record · Phase 2

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

A Phase 2 study of Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
7
Study locations

NCT07209449: Recruiting Phase 2 study of Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT07209449 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 75 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (86% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07209449, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
7
Study locations

Study Summary

The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.

Primary Outcome

according to RECIST 1.1 criteria. Defined as the percentage of patients with complete response (CR) + partial response (PR)\] after initiating therapy.

Conditions Studied

Interventions

  • DRUG Abemaciclib
  • DRUG Elacestrant

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-10-01
Est. Completion 2028-10-01
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT07209449 shows while recruiting

NCT07209449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.

NCT07209449 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT07209449 about?

NCT07209449 is a clinical study titled "A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer". The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.

What is the current status of trial NCT07209449?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-10-01. Estimated completion is 2028-10-01.

What conditions does trial NCT07209449 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT07209449?

The interventions under investigation include: Abemaciclib (DRUG), Elacestrant (DRUG).

Who is sponsoring clinical trial NCT07209449?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07209449 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07209449's enrollment target sits among peer trials

75 103rd of 181 higher than 79 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07209449, the US trial registry maintained by the National Library of Medicine. NCT07209449 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.